Truist Financial restated their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a report issued on Friday, Benzinga reports. Truist Financial currently has a $1,200.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $1,135.00. Other equities research analysts have also recently issued reports about the […]

View Entire Post